AU Patent

AU2021380319A1 — Pharmaceutical composition for oral administration of edaravone and method of administering same

Assigned to Tanabe Pharma Corp · Expires 2023-06-22 · 3y expired

What this patent protects

Provided is a pharmaceutical composition having edaravone as an active ingredient for oral administration or administration equivalent thereto.　The pharmaceutical composition of the present invention contains edaravone as an active ingredient and is characterized by being adminis…

USPTO Abstract

Provided is a pharmaceutical composition having edaravone as an active ingredient for oral administration or administration equivalent thereto.　The pharmaceutical composition of the present invention contains edaravone as an active ingredient and is characterized by being administered orally or intragastrically during any one of a first time interval selected from the group consisting of 1)-3): 1) eight hours or more after ingestion when a high-fat meal has been ingested, 2) four hours or more after ingestion when a standard meal has been ingested, 3) two hours or more after ingestion when a light meal has been ingested.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021380319A1
Jurisdiction
AU
Classification
—
Expires
2023-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.